Since the natural binding affinity between the TCR of cytotoxic CD8+ T cell for self-antigen-presented MHC is low due to the self-tolerance mechanism, the design of ImmTAC enables the possibility to target tumor-associated antigens using an artificial TCR [52]. The gene discussed is CD8A; the disease is neoplasm.